2019
DOI: 10.1093/ofid/ofz360.1227
|View full text |Cite
|
Sign up to set email alerts
|

1363. Does Genotypic Testing Improve Treatment Outcomes in Drug-Resistant Tuberculosis?

Abstract: BackgroundTreatment of drug-resistant tuberculosis (DR-TB) requires toxic and complex drug regimens. Dismal outcomes occur due to a delay in the report of susceptibility results. WHO endorses genotypic tests like line probe assay (Mtbdrsl) for an early diagnosis enabling start of robust treatment regimens. Data correlating Mtbdrsl and specific mutations with outcome are rare.MethodsA concurrent cohort study was conducted on all patients diagnosed to have DR-TB between January 2016 and June 2017 in the departme… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles